OMS906
Omeros
['obinu']
omeros corporation s pre-specified interim analysis of the phase 1b clinical trial of oms906, our masp-3 inhibitor in paroxysmal nocturnal hemoglobinuria, was identified as a top 5 late-breaking submission for #eha2023 presentation this sunday, june 11
Life Science